

DAFTAR PUSTAKA

1. WHO (2019). World Health Organization. World maternal mortality. <https://www.who.int/news-room/fact-sheets/detail/maternal-mortality> – Diakses November 2022.
2. United Nations Children's Fund (2021). UNICEF data. Maternal mortality rates and statistics. <https://data.unicef.org/topic/maternal-health/maternal-mortality/> – Diakses Januari 2023.
3. Kementerian Kesehatan Republik Indonesia. Profil kesehatan Indonesia tahun 2021. Jakarta; 2022.
4. Presiden Republik Indonesia. Peraturan Presiden Republik Indonesia Nomor 18 Tahun 2020 Tentang Rencana Pembangunan Jangka Menengah Nasional 2020 - 2024 Republik Indonesia. 2020.
5. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2021. 2021.
6. Tikkanen R, Gunja MZ, FitzGerald M, Zephyrin L. Maternal mortality and maternity care in the United States compared to 10 other developed countries. 2020.
7. Kuehn BM. Cardiologists urged to help reduce heart-related maternal mortality. *Circulation*. Lippincott Williams and Wilkins; 2020;1013–4.
8. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. *European Journal of Heart Failure*. 2010;12:767–78.
9. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. *Mayo Clin Proc*. 2005;80(12):1602–6.
10. Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy

- in the United States: A nationwide population-based study. *J Am Heart Assoc.* 2014;3(3).
11. Munirwan H, Siswanto BB, Candrasatria RM, Asbarinsyah NA, Callista MA, Soesanto AM. Epidemiology and clinical characteristics of peripartum cardiomyopathy in National Cardiac Center Harapan Kita Hospital. 2015.
 12. Rinta F, Ketaren I, Wicaksono A. Gambaran Kardiomiopati Peripartum di Rumah Sakit Santo Antonius Pontianak Tahun 2008-2012. *Jurnal Cerebellum.* 2016;2.
 13. Arfianda D, Wicaksono B, Erza Gumilar K. Characteristics of peripartum cardiomyopathy pregnancy and preeclampsia in Dr Soetomo. *Maj Obs Gin.* 2019;27(1):2014–6.
 14. Khairunnisa NA, Yanni M, Afriwardi, Amelin F, Fadil M, Anggrainy F. Gambaran faktor-faktor yang memengaruhi keberhasilan terapi kardiomiopati peripartum di RSUP Dr. M. Djamil Padang Tahun 2016 – 2019 (thesis).2020.
 15. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: A systematic review and meta-analysis. *J Am Coll Cardiol.* 2013;62(18):1715–23.
 16. Gammill HS, Chettier R, Brewer A, Roberts JM, Shree R, Tsigas E, et al. Cardiomyopathy and preeclampsia: Shared Genetics. *Circulation.* 2018;138(21):2359–66.
 17. Davis MB, Arany Z, McNamara DM, Golland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol. NLM (Medline);* 2020;75:207–21.
 18. Ziccardi MR, Siddique MS (2022). Peripartum Cardiomyopathy. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK482185/> - Diakses Januari 2023.
 19. Yeboah J, Rodriguez CJ, Qureshi W, Liu S, Carr JJ, Lima JA, et al. Prognosis of low normal left ventricular ejection fraction in an

- asymptomatic population-based adult cohort: The multiethnic study of atherosclerosis. *J Card Fail*. 2016;22(10):763–8.
20. Pieper PG. Predicting the future in peripartum cardiomyopathy. *Heart*. 2012;99:295–6.
 21. Hassen LJ, Roble S. Peripartum cardiomyopathy. In: *Encyclopedia of cardiovascular research and medicine*. Elsevier. 2018;42–8.
 22. Lewey J, Levine LD, Elovitz MA, Irizarry OC, Arany Z. Importance of early diagnosis in peripartum cardiomyopathy. *Hypertension*. 2020;75(1):91–7.
 23. Smith GB, Isaacs R, Andrews L, Wee MYK, van Teijlingen E, Bick DE, et al. Vital signs and other observations used to detect deterioration in pregnant women: an analysis of vital sign charts in consultant-led UK maternity units. *Int J Obstet Anesth*. 2017;30:44–51.
 24. Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: A meta-analysis. *CMAJ*. 2016;188(3):53–63.
 25. Biswas PK, Basu S, Mitra K, Chowdhury S, Chatterjee BP. Heart rate variability in dilated cardiomyopathy. *Indian Heart J*. 2000;52(2):187–91.
 26. Cooney R, Scott JR, Mahowald M, Langen E, Sharma G, Kao DP, et al. Heart rate as an early predictor of severe cardiomyopathy and increased mortality in peripartum cardiomyopathy. *Clin Cardiol*. 2022;45(2):205–13.
 27. Libhaber E, Sliwa K, Bachelier K, Lamont K, Böhm M. Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. *Int J Cardiol*. 2015;190:376–82.
 28. Hoevermann J, Viljoen CA, Manning K, Baard J, Hahnle L, Ntsekhe M, et al. The prognostic significance of the 12-lead ECG in peripartum cardiomyopathy. *Int J Cardiol*. 2019;276:177–84.
 29. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure

- Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *Eur J Heart Fail*;21(7):827–43.
30. American Heart Association. Classification of functional capacity and objective assessment. 1994.
 31. Merzouk FZ, Oualim S, Sabry M. Peripartum cardiomyopathy: The Hidden Enemy. London; 2021.
 32. Samonte VI, Ngalob QG, Mata GDB, Aherrera JAM, Reyes E, Punzalan FER. Clinical and echocardiographic profile and outcomes of peripartum cardiomyopathy: the Philippine General Hospital experience. *Heart Asia*. 2013;5(1):245–9.
 33. Chee KH, Azman W. Prevalence and outcome of peripartum cardiomyopathy in Malaysia. *Int J Clin Pract*. 2009;63(5):722–5.
 34. Espinoza J, Vidaeff A, Pettker CM, Simhan H. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. 2020.
 35. Tsatsaris V, Cabrol D, Carbonne B. Pharmacokinetics of tocolytic agents. *Clin Pharmacokinet*. 2004;43.
 36. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: An ominous diagnosis. *Am J Obstet Gynecol*. 1997;176.
 37. Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM. Peripartum heart failure associated with prolonged tocolytic therapy. *Am J Obstet Gynecol*. 1993;168(2):493–5.
 38. Li PC, Chang HR, Kao SP. Peripartum cardiomyopathy and acute heart failure associated with prolonged tocolytic therapy in pregnancy. *Medicine*. 2021;100(34).
 39. Kementerian Kesehatan Republik Indonesia. Batas ambang indeks masa tubuh (IMT) untuk Indonesia. 2019.
 40. Cho SH, Leonard SA, Lyndon A, Main EK, Abrams B, Hameed AB, et al. Pre-pregnancy obesity and the risk of peripartum cardiomyopathy. *Am J Perinatol*. 2021;38(12):1289–96.
 41. Ahmed I, Masroor M, Qamar R, Hashmi KA, Sattar A, Imran K, et al. Risk factors associated with peripartum cardiomyopathy. *Pakistan Heart Journal*. 2003;36:4–8.

42. Arany Z, Elkayam U. Peripartum cardiomyopathy. *Circulation*. 2016;133(14):1397–409.
43. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. *New England Journal of Medicine*. 2016;374(3):233–41.
44. Cénac A, Gaultier Y, Devillechabrolle A, Moulias R. Enterovirus infection in peripartum cardiomyopathy. *Lancet*. 1988.
45. Karaye KM, Yahaya IA, Lindmark K, Henein MY. Serum selenium and ceruloplasmin in nigerians with peripartum cardiomyopathy. *Int J Mol Sci*. 2015;16(4):7644–54.
46. Shani H, Kuperstein R, Berlin A, Arad M, Goldenberg I, Simchen MJ. Peripartum cardiomyopathy – risk factors, characteristics and long-term follow-up. *J Perinat Med* 2015;43(1):95–101.
47. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. *Cell*. 2007;128(3):589–600.
48. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. *Nature*. 2012;485(7398):333–8.
49. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. *J Am Coll Cardiol*. 2000;35(3):701–5.
50. Lamparter S, Pankuweit S, Maisch B. Clinical and immunologic characteristics in peripartum cardiomyopathy. *Int J Cardiol*. 2007;118(1):14–20.
51. Warraich RS, Sliwa K, Damasceno A, Carraway R, Sundrom B, Arif G, et al. Impact of pregnancy-related heart failure on humoral immunity: Clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. *Am Heart J*. 2005;150(2):263–9.

52. Bello NA, Arany Z. Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. *Trends in Cardiovascular Medicine*. Elsevier Inc.; 2015;25:499–504.
53. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: A multicentre randomized study. *Eur Heart J*. 2017;38(35):2671–9.
54. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. *Eur J Heart Fail*. 2002;4(3):305–9.
55. Tiwari R, Kumar R, Malik S, Raj T, Kumar P. Analysis of heart rate variability and implication of different factors on heart rate variability. *Curr Cardiol Rev*. 2021;17(5).
56. Jensen MT. Resting heart rate and relation to disease and longevity: past, present and future. *Scandinavian Journal of Clinical and Laboratory Investigation*. Taylor and Francis Ltd; 2019;79:108–16.
57. Coad F, Frise C. Tachycardia in pregnancy: When to worry. *Clinical Medicine, Journal of the Royal College of Physicians of London*. 2021;21(5):E434–7.
58. Green LJ, Pullon R, Mackillop LH, Gerry S, Birks J, Salvi D, et al. Postpartum-specific vital sign reference ranges. *Obstetrics and gynecology*. 2021;137(2):295–304.
59. Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JGF, et al. Heart rate: A prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. *Eur J Heart Fail*. 2014;16(1):76–85.
60. Hori M, Okamoto H. Heart rate as a target of treatment of chronic heart failure. *Journal of Cardiology*. 2012;60:86–90.
61. Kosaraju A, Goyal A, Grigorova Y, Makaryus AN (2022). *Left Ventricular Ejection Fraction*. Treasure Island (FL): StatPearls Publishing.

<https://www.ncbi.nlm.nih.gov/books/NBK459131/> – Diakses Januari 2023

62. Mayala HA, Mafuru M, Mkangala A, Mayala M, Pallangyo P, Minja D, et al. Factors influencing left ventricular ejection fraction in patients with coronary microvascular disease and obstructive coronary artery disease. *BMC Res Notes*. 2020;13(1).
63. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European Heart Journal*. Oxford University Press; 2021;42:3599–726.
64. Lang RM, Badano LP, Victor MA, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography*. 2015;28(1):1-39.e14.
65. Cikes M, Solomon SD. Beyond ejection fraction: An integrative approach for assessment of cardiac structure and function in heart failure. *European Heart Journal*. Oxford University Press; 2016;37:1642–50.
66. Kurgansky KE, Schubert P, Parker R, Djousse L, Riebman JB, Gagnon DR, et al. Association of pulse rate with outcomes in heart failure with reduced ejection fraction: A retrospective cohort study. *BMC Cardiovasc Disord*. 2020;20(1).
67. Ricci DR, Orlick AE, Edwin Alderman FL, Neil F, Daughters GT, Edward Stinson MB, et al. Influence of heart rate on left ventricular ejection fraction in human beings. *Am J Cardiol*. 1979;44(3): 447-51.
68. Logeart D, Gueffet JP, Rouzet F, Pousset F, Chavelas C, Solal AC, et al. Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: A pilot study. *Eur J Heart Fail*. 2009 Jan;11(1):53–7.
69. Sopiyyudin DM. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. 3rd ed. Jakarta: Salemba Medika; 2010.

70. Velagaleti RS, Vetter J, Parker R, Kurgansky KE, Sun Y V., Djousse L, et al. Change in Left Ventricular Ejection Fraction with Coronary Artery Revascularization and Subsequent Risk for Adverse Cardiovascular Outcomes. *Circ Cardiovasc Interv.* 2022;15(4):E011284.
71. Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: A nationwide population-based study. *J Am Heart Assoc.* 2014;3(3).
72. Putra ICS, Irianto CB, Raffaello WM, Suciadi LP, Prameswari HS. Pre-pregnancy obesity and the risk of peripartum cardiomyopathy: A systematic review and meta-analysis. *Indian Heart J.* 2022;74(3):235–8.
73. Timoh T, Bloom ME, Siegel RR, Wagman G, Lanier GM, Vittorio TJ. A perspective on obesity cardiomyopathy. *Obesity Research and Clinical Practice.* 2012;6.
74. Zhang Y, Zhao Q, Biscetti F, Michos ED. Association between parity and markers of inflammation: The multi-ethnic study of atherosclerosis. *Front Cardiovasc Med.* 2022; 9
75. Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H, et al. Hypertensive disorders of pregnancy and peripartum cardiomyopathy: A nationwide cohort study. *PLoS One.* 2019;14(2).
76. Melchiorre K, Sharma R, Thilaganathan B. Cardiovascular implications in preeclampsia: An overview. *Circulation.* 2014;130(8):703–14.
77. Melchiorre K, Sharma R, Khalil A, Thilaganathan B. Maternal cardiovascular function in normal pregnancy: Evidence of maladaptation to chronic volume overload. *Hypertension.* 2016;67(4):754–62.
78. Wu VCC, Chen TH, Yeh JK, Wu M, Lu CH, Chen SW, et al. Clinical outcomes of peripartum cardiomyopathy: A 15-year nationwide population-based study in Asia. *Medicine United States.* 2017;96(43).
79. Lee S, Cho GJ, Park GU, Kim LY, Lee TS, Kim DY, et al. Incidence, Risk Factors, and Clinical Characteristics of Peripartum Cardiomyopathy in South Korea. *Circ Heart Fail.* 2018;11(4).

80. Dhawan V, Brookes ZLS, Kaufman S. Long-term effects of repeated pregnancies (multiparity) on blood pressure regulation. *Cardiovasc Res.* 2004;64(1):179–86.
81. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, et al. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. *Circulation.* 2005;111:2050–5.
82. Hoevelmann J, Engel ME, Muller E, Hohlfeld A, Böhm M, Sliwa K, et al. A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis. *Eur J Heart Fail.* 2022;24(9):1719–36.
83. Sliwa K, Arrigo M, Azibani F, Bauersachs J, Briton O, Cauldwell M, et al. *Peripartum Cardiomyopathy: From Pathophysiology to Management.* Peripartum Cardiomyopathy. Oxford: Elsevier; 2021.
84. Givertz MM. Peripartum cardiomyopathy. *Circulation.* 2013;127(20).
85. Herman LL, Padala SA, Ahmed I, Bashir K (2023). Angiotensin-Converting Enzyme Inhibitors (ACEI). Treasure Island (FL): StatPearls Publishing. <https://pubmed.ncbi.nlm.nih.gov/28613705/> – Diakses Juli 2023
86. Hill RD, Prabhakar, Vaidya N (2023). Angiotensin II Receptor Blockers. Treasure Island (FL): StatPearls Publishing. <https://pubmed.ncbi.nlm.nih.gov/30725712/> - Diakses Juli 2023
87. Achmad C, Iqbal M, Karwiyk G, Prameswari HS, Febrianora M. T-Peak to T-End Improvements After Beta-Blocker Administration in Peripartum Cardiomyopathy Patients. *Cardiol Res.* 2020;11(3):185–91.
88. Goland S, Bitar F, Modi K, Safirstein J, Ro A, Mirocha J, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. *J Card Fail.* 2011;17(5):426–30.
89. Dzudie A, Hongieh Abanda M, Nkoke C, Barche B, Damasceno A, Edwards C, et al. Clinical characteristics and outcomes of black African

heart failure patients with preserved, mid-range, and reduced ejection fraction: a post hoc analysis of the THESUS-HF registry. *ESC Heart Fail.* 2021;8(1):238–49.

90. Trongtorsak A, Kittipibul V, Mahabir S, Ibrahim M, Saint Croix GR, Hernandez GA, et al. Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis. *Heart Fail Rev.* 2022;27(2):533–43.
91. Kian W, Zemel M, Kestenbaum EH, Alguayn W, Shvarts B, Sharb AA, et al. *Cardiomyopathy Etiologies, Symptoms and Management* [Internet]. IntechOpen. 2021.
92. Nanchen D, Leening MJG, Locatelli I, Cornuz J, Kors JA, Heeringa J, et al. Resting heart rate and the risk of heart failure in healthy adults the rotterdam study. *Circ Heart Fail.* 2013;6(3):403–10.
93. Valentini M, Parati G. Variables influencing heart rate. *Progress in Cardiovascular Diseases.* 2009;52(1):11 – 19

